gemcitabine + vandetanib

Gemcitabine + vandetanib is an investigational combination therapy consisting of gemcitabine, a nucleoside analog and antimetabolite chemotherapeutic agent, and vandetanib, an orally available small molecule multi-tyrosine kinase inhibitor. Gemcitabine inhibits DNA synthesis by incorporating into DNA strands during replication, leading to cell death. Vandetanib targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, specifically inhibiting vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) pathways. This combination has been studied primarily for the treatment of advanced pancreaticobiliary cancers such as pancreatic cancer and cholangiocarcinoma[1][2][6]. Clinical trials have shown that the regimen is generally well tolerated at standard doses with promising antitumor activity.